Faculty of 1000 evaluation for A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.

Ulla Feldt-Rasmussen
  • October 2013, Faculty of 1000, Ltd.
  • DOI: 10.3410/f.718113892.793485355

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication

http://dx.doi.org/10.3410/f.718113892.793485355

The following have contributed to this page: Professor Ulla Feldt-Rasmussen